Did Five Year CARVYKTI Data Just Shift Legend Biotech's (LEGN) Investment Narrative?

• Legend Biotech reported five-year follow-up results from the CARTITUDE-2 Cohort A trial, where 50% of relapsed or refractory multiple myeloma patients remained alive and progression-free without maintenance treatment five years after a single CARVYKTI infusion.
• This kind of long-duration, treatment-free remission signal, combined with a stable safety profile over five years, directly affects how investors think about CARVYKTI’s clinical staying power and potential treatment positioning in multiple myeloma.
• We will look at how Legend Biotech's investment narrative is shaped by five-year treatment-free remission data from CARVYKTI.

Scan how Legend Biotech’s CAR-T data fits into the broader opportunity set by reviewing hand-picked 35 healthcare AI stocks that are pushing the boundaries of tech-enabled treatments and long-duration outcomes.

Legend Biotech Investment Narrative Recap

To own Legend Biotech, you need to believe CARVYKTI can support a durable cell therapy franchise while the broader pipeline slowly reduces reliance on a single product. The five year CARTITUDE 2 data strengthens the case that the current lead asset has staying power in relapsed or refractory multiple myeloma. The biggest near term swing factor still looks like execution on manufacturing, supply, and broader access in the US and Europe.

The main operational risk does not really change with this update. Legend Biotech remains heavily concentrated in CARVYKTI and continues to run at a loss, with net income at a loss of US$91.5 million on US$1.27b of revenue. High R&D and commercialization spend, plus dependence on partners for global roll out, still sit at the center of the risk profile.

The fresh CARTITUDE 2 data aligns with earlier readouts that underpinned trials such as CARTITUDE 5 and 6, which are aimed at moving CARVYKTI into earlier treatment settings. For investors, the operational link is straightforward: longer treatment free survival in patients after fewer prior lines can support a broader addressable pool if regulators and clinicians accept these outcomes alongside earlier data sets.

At the same time, the results keep competitive and safety scrutiny high. Legend Biotech and its partner need to keep showing consistent manufacturing quality and a predictable safety profile while rivals advance bispecifics and next generation cell therapies. Your thesis around future catalysts likely rests less on this single cohort and more on how quickly the firm can translate the broader data package into potential label expansions, smoother logistics, and a clearer path toward profitability.

What The Long Term Legend Biotech Story Assumes

Legend Biotech's long term setup is being framed around analyst expectations that link CARVYKTI's clinical momentum to a sizeable shift in the financial profile over the next few years. The current report pegs revenue growth assumptions at 19.0% per year over the coming three years, with profit margins moving from a loss position of 7.2% today to a positive 18.6% over that same period. That is a meaningful swing in profitability for any developer of cell therapies, and it gives you a sense of how much operational scaling and cost discipline are being baked into forward models.

On earnings, the gap between where Legend Biotech is today and where the analyst consensus sits is wide. The business currently reports a loss of US$91.5 million on its income line. Consensus estimates point to earnings of US$399.0 million by 2029, which is a value change of roughly US$490 million from current earnings. That shift would move the company from loss making into positive net income using the same currency, a transition that depends heavily on CARVYKTI performance and on whether the broader pipeline starts to contribute in a more material way.

Legend Biotech's narrative projects US$2.1b revenue and US$399.0 million earnings by 2029. This requires 19.0% yearly revenue growth and an earnings increase of roughly US$490 million from current earnings of a US$91.5 million loss.

Those future earnings assumptions also feed directly into how the stock is being valued today. To line up with the consensus price target, analysts are using a P/E multiple of 32.7x on the projected 2029 earnings of US$399.0 million. That is higher than the 17.1x P/E currently quoted for the broader US biotechs group in the same report. It means the current thesis does not just rely on Legend Biotech reaching those earnings levels. It also assumes investors will be willing to pay a premium multiple on those profits relative to peers.

There is also a spread of views inside that earnings number that you should not ignore. The most optimistic forecasts call for US$775.6 million in profit by roughly 2029, while the most cautious sit at US$111.6 million. That range underlines how much uncertainty still sits around CARVYKTI uptake, competitive dynamics in multiple myeloma, and the timing and impact of pipeline assets. It also shows why treating any single forecast as a precise roadmap can be risky.

Capital structure and discounting assumptions round out the picture. Analyst models in this report expect the share count to increase by 4.92% per year over the next three years as Legend Biotech continues to fund R&D and build out manufacturing. Future cash flows are being discounted back at 7.6% to 7.62%, a rate that tries to balance the company specific risks of late stage oncology development with broader market return expectations. For you as an investor, those inputs are levers you can adjust based on your own view of risk, dilution, and what kind of return profile feels reasonable for a cell therapy platform at this stage.

Uncover why Legend Biotech's fair value indicates a 142% potential upside to its current price that may not last much longer.

Exploring Other Perspectives

The biggest swing factor in the alternate Legend Biotech story is not the science. It is pricing and reimbursement pressure. The most cautious analysts were working off revenue assumptions of about US$2.0b and earnings of US$108.2 million by 2029 before this new CARTITUDE 2 update. That is far below consensus and shows how sharply opinions can differ. Use this wide spread as a prompt to explore several viewpoints and decide how much weight to give long term remission data in your own framework.

Explore 3 other Legend Biotech fair value estimates, including one that suggests it could be worth just $24.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Legend Biotech research is our analysis highlighting 4 key rewards that could impact your investment decision.
• See our latest analysis for Legend Biotech. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Legend Biotech's overall financial health at a glance.

Looking For More Investment Ideas Beyond Legend Biotech?

If the Legend Biotech story has sharpened your sense of risk, reward, and time horizon, it can be useful to line it up against other opportunities with very different financial profiles. The Simply Wall St Screener gives you a quick way to compare this kind of high-intensity cell therapy exposure with companies that lean more on balance sheet strength, steady cash generation, or under-the-radar quality.

• If you want potential upside with tighter risk controls, start by scanning a set of 31 resilient stocks with low risk scores that may better match a more defensive playbook.
• For investors hunting for quality at a sensible entry point, check out a hand picked group of 28 high quality undervalued stocks that combine fundamentals with more grounded pricing.
• Those who prefer stability and room for compounding income can review a focused collection of 7 dividend fortresses that may help anchor the more volatile parts of a portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com